Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kantor, R.
Right arrow Articles by Achiron, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kantor, R.
Right arrow Articles by Achiron, A.
Related Collections
Right arrow Multiple sclerosis
Right arrow Natural history studies (prognosis)
Right arrow Association studies in genetics

Neurology 2003;61:238-240
© 2003 American Academy of Neurology
Brief Communications

A mutated CCR5 gene may have favorable prognostic implications in MS

Rami Kantor, MD, Mary Bakhanashvili, PhD and Anat Achiron, MD PhD

From the Division of Infectious Diseases (Drs. Kantor and Bakhanashvili) and Multiple Sclerosis Center (Dr. Achiron), Sheba Medical Center, Tel-Hashomer, Israel.

Address correspondence and reprint requests to Dr. A. Achiron, Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, 52621, Israel; e-mail: achiron{at}post.tau.ac.il

The authors investigated the association between {Delta}32CCR5, a mutated allele of the chemokine receptor CCR5, and disease progression in 256 patients with multiple sclerosis (MS). The mutated allele frequency in the study cohort was 7.4%, similar to that reported in the general Israeli population. Progression to disability was prolonged in {Delta}32CCR5 homozygotes and heterozygotes compared with MS patients with the CCR5 wild-type genotype (p < 0.005). Mutated CCR5 allele may be considered a favorable prognostic factor in MS.




This article has been cited by other articles:


Home page
 Mult SclerHome page
S. Ristic, L. Lovrecic, N. Starcevic-Cizmarevic, B. Brajenovic-Milic, S. S. Jazbec, V. Barac-Latas, D. Vejnovic, J. Sepcic, M. Kapovic, and B. Peterlin
No association of CCR5D32 gene mutation with multiple sclerosis in Croatian and Slovenian patients
Multiple Sclerosis, June 1, 2006; 12(3): 360 - 362.
[Abstract] [PDF]

Home page
 Mult SclerHome page
F Sellebjerg, C Ross, N Koch-Henriksen, P S. Sorensen, J L Frederiksen, K Bendtzen, and T L Sorensen
CD26+CD4+T cell counts and attack risk in interferon-treated multiple sclerosis
Multiple Sclerosis, December 1, 2005; 11(6): 641 - 645.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
E. M. Frohman, M. Filippi, O. Stuve, S. G. Waxman, J. Corboy, J. T. Phillips, C. Lucchinetti, J. Wilken, N. Karandikar, B. Hemmer, et al.
Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence and New Hypotheses for Future Directions
Arch Neurol, September 1, 2005; 62(9): 1345 - 1356.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.